CVS Health Corporation
CVS Health Corporation (CVS) Stock Competitors & Peer Comparison
See (CVS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CVS | $66.73 | +0.00% | 87B | 19.11 | $3.59 | +3.88% |
| UNH | $271.49 | +0.00% | 275.5B | 13.17 | $23.10 | +2.78% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | N/A |
| CI | $290.35 | +0.00% | 79.2B | 16.28 | $18.23 | +1.94% |
| ELV | $295.43 | +0.00% | 69.7B | 13.12 | $23.58 | +2.15% |
| HUM | $281.34 | +0.00% | 34.4B | 21.94 | $13.05 | +1.23% |
| CNC | $26.93 | +0.00% | 14B | 6.92 | $4.12 | N/A |
| MOH | $159.63 | +0.00% | 9.1B | 8.26 | $20.28 | N/A |
| OSCR | $14.68 | +0.00% | 4B | -22.65 | -$0.69 | N/A |
| ALHC | $14.82 | +0.00% | 3B | -55.74 | -$0.27 | N/A |
Stock Comparison
CVS vs UNH Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, UNH has a market cap of 275.5B. Regarding current trading prices, CVS is priced at $66.73, while UNH trades at $271.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas UNH's P/E ratio is 13.17. In terms of profitability, CVS's ROE is +0.06%, compared to UNH's ROE of +0.22%. Regarding short-term risk, CVS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check UNH's competition here
CVS vs ANTM Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CVS is priced at $66.73, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CVS's ROE is +0.06%, compared to ANTM's ROE of +0.18%. Regarding short-term risk, CVS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ANTM's competition here
CVS vs CI Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, CI has a market cap of 79.2B. Regarding current trading prices, CVS is priced at $66.73, while CI trades at $290.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas CI's P/E ratio is 16.28. In terms of profitability, CVS's ROE is +0.06%, compared to CI's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CI's competition here
CVS vs ELV Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, ELV has a market cap of 69.7B. Regarding current trading prices, CVS is priced at $66.73, while ELV trades at $295.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas ELV's P/E ratio is 13.12. In terms of profitability, CVS's ROE is +0.06%, compared to ELV's ROE of +0.13%. Regarding short-term risk, CVS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ELV's competition here
CVS vs HUM Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, HUM has a market cap of 34.4B. Regarding current trading prices, CVS is priced at $66.73, while HUM trades at $281.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas HUM's P/E ratio is 21.94. In terms of profitability, CVS's ROE is +0.06%, compared to HUM's ROE of +0.09%. Regarding short-term risk, CVS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check HUM's competition here
CVS vs CNC Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, CNC has a market cap of 14B. Regarding current trading prices, CVS is priced at $66.73, while CNC trades at $26.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas CNC's P/E ratio is 6.92. In terms of profitability, CVS's ROE is +0.06%, compared to CNC's ROE of +0.08%. Regarding short-term risk, CVS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CNC's competition here
CVS vs MOH Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, MOH has a market cap of 9.1B. Regarding current trading prices, CVS is priced at $66.73, while MOH trades at $159.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas MOH's P/E ratio is 8.26. In terms of profitability, CVS's ROE is +0.06%, compared to MOH's ROE of +0.25%. Regarding short-term risk, CVS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check MOH's competition here
CVS vs OSCR Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, OSCR has a market cap of 4B. Regarding current trading prices, CVS is priced at $66.73, while OSCR trades at $14.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas OSCR's P/E ratio is -22.65. In terms of profitability, CVS's ROE is +0.06%, compared to OSCR's ROE of -0.14%. Regarding short-term risk, CVS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check OSCR's competition here
CVS vs ALHC Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, ALHC has a market cap of 3B. Regarding current trading prices, CVS is priced at $66.73, while ALHC trades at $14.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas ALHC's P/E ratio is -55.74. In terms of profitability, CVS's ROE is +0.06%, compared to ALHC's ROE of -0.44%. Regarding short-term risk, CVS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ALHC's competition here
CVS vs CLOV Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, CLOV has a market cap of 1.4B. Regarding current trading prices, CVS is priced at $66.73, while CLOV trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas CLOV's P/E ratio is -33.12. In terms of profitability, CVS's ROE is +0.06%, compared to CLOV's ROE of -0.13%. Regarding short-term risk, CVS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CLOV's competition here
CVS vs BHG Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CVS is priced at $66.73, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas BHG's P/E ratio is -0.12. In terms of profitability, CVS's ROE is +0.06%, compared to BHG's ROE of -0.47%. Regarding short-term risk, CVS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BHG's competition here
CVS vs BMGL Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, BMGL has a market cap of 37M. Regarding current trading prices, CVS is priced at $66.73, while BMGL trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas BMGL's P/E ratio is 197.00. In terms of profitability, CVS's ROE is +0.06%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, CVS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BMGL's competition here
CVS vs MRAI Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, MRAI has a market cap of 24.9M. Regarding current trading prices, CVS is priced at $66.73, while MRAI trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas MRAI's P/E ratio is -0.50. In terms of profitability, CVS's ROE is +0.06%, compared to MRAI's ROE of +0.75%. Regarding short-term risk, CVS is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check MRAI's competition here
CVS vs NIVF Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, NIVF has a market cap of 3.5M. Regarding current trading prices, CVS is priced at $66.73, while NIVF trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas NIVF's P/E ratio is -0.08. In terms of profitability, CVS's ROE is +0.06%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, CVS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check NIVF's competition here
CVS vs IVF Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, IVF has a market cap of 1.5M. Regarding current trading prices, CVS is priced at $66.73, while IVF trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas IVF's P/E ratio is -0.01. In terms of profitability, CVS's ROE is +0.06%, compared to IVF's ROE of -5.72%. Regarding short-term risk, CVS is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check IVF's competition here
CVS vs GTS Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CVS is priced at $66.73, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas GTS's P/E ratio is 10.41. In terms of profitability, CVS's ROE is +0.06%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CVS is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check GTS's competition here
CVS vs MGLN Comparison August 2025
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 87B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CVS is priced at $66.73, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 19.11, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CVS's ROE is +0.06%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CVS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check MGLN's competition here